<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 10-QSB

 Quarterly Report Pursuant to Section 13 Or 15(D) Of The Securities Act Of 1934

                  For the quarterly period ended March 31, 2003

                        Commission file number: 2 90 519

                           APPLIED DNA SCIENCES, INC.
        (Exact name of small business issuer as specified in its charter)

                  NEVADA                       59-2262718
(State or other jurisdiction of         (IRS Employee Identification No.)
 incorporation or organization)

          9255 West Sunset Boulevard, Suite 805, Los Angeles, CA 90069
                    (Address of principal executive offices)

                                 (310) 860-1362
                           (Issuer's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

Yes      X                 No
         ------------------

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date:

Common Stock, $0.0001 par value                      23,152,662
       (Class)                              (Outstanding as of March 31, 2003)

<PAGE>




                                Table of Contents

PART I.  FINANCIAL INFORMATION

         Item 1.  Financial Statements (Unaudited)

         Item 2.  Management's Discussion and Analysis or Plan of Operation

          Item 3.  Controls and Procedures


PART II.  OTHER INFORMATION

         Item 1.  Legal Proceedings

         Item 2.  Changes in Securities

         Item 3.  Defaults Upon Senior Securities

         Item 4.  Submission of Matters to a Vote of Security Holders

         Item 5.  Other Information

         Item 6.  Exhibits and Reports on Form 8-K

         Signatures


<PAGE>


PART I.  FINANCIAL INFORMATION ( Unaudited )


Condensed Consolidated Balance Sheets at  March 31, 2003 and September 30, 2002

Condensed Consolidated Statements of Losses for the three months ended March 31,
2003 ,Six Months Ended March 31, 2003 and for the period September 16, 2002
(Date of Inception) through March 31, 2003.

Condensed Consolidated Statement of Deficiency in stockholders' equity for the
period September 16, 2002 (date of inception ) through March 31, 2003.

Condensed Consolidated Statements of Cash Flows for Six Months Ended March 31,
2003 and For the period September 16, 2002 (Date of Inception) through March 31,
2003.

Notes to Condensed  Consolidated Financial Statements ..




<PAGE>







                           APPLIED DNA SCIENCES, INC.
                          (A Development Stage Company)
                      CONDENSED CONSOLIDATED BALANCE SHEET
<TABLE>
<CAPTION>

                                                      March 31, 2003    September 30, 2002
                                                       (unaudited)
<S>                                                      <C>               <C>
ASSETS
Current Assets:

Cash and Equivalents                                 $        25,853   $                 -

Other Assets                                         $         8,180                     -

Total  Assets                                        $        34,033   $                 -
                                                     ================  ====================




LIABILITIES AND DEFICIENCY IN
STOCKHOLDER'S EQUITY
Current Liabilities:
Accounts Payable and Accrued Expenses                $       106,103   $                 -
Due Related Parties                                           72,092                10,612
                                                     ----------------  --------------------

Total Current Liabilities                                    178,195                10,612

Deficiency in Stockholder's Equity:

Preferred Stock, par value $0.0001 per share;
 10,000,000 shares authorized; none issued at March
31, 2003                                                           -                     -
Common Stock, par value, $.0001 per share;
 authorized 100,000,000 shares;  23,152,662 shares
 issued and outstanding at March 31, 2003                      2,315                 1,000
Stock Subscription Receivable                                 (2,600)                    -
Additional Paid in Capital                                   464,751                     -
Deficiency accumulated during development stage             (608,628)              (11,612)
                                                     ----------------  --------------------
Total Deficiency in Stockholder's Equity                    (144,162)              (10,612)
                                                     ----------------  --------------------
                                                     $        34,033   $                 -
                                                     ================  ====================

</TABLE>

 The accompanying notes to unaudited condensed consolidated financial statements

<PAGE>





                           APPLIED DNA SCIENCES, INC.
                          (A Development Stage Company)
                   CONDENSED CONSOLIDATED STATEMENT OF LOSSES

<TABLE>
<CAPTION>


                                  For the three For the six   For the Period September 16
                                      months        months     2002 (Date of Inception)
                                March 31, 2003 March 31, 2003  through March 31, 2003

<S>                                   <C>               <C>           <C>

Revenues                       $             -   $         -   $         -
                               ----------------  ------------  ------------

Costs and Expenses:
  General and Administrative           432,984   $   597,016       608,628
                               ----------------  ------------  ------------
  Total Operating Expenses             432,984       597,016       608,628

Loss from Operations                  (432,984)     (597,016)     (608,628)

Income (taxes) benefit                       -             -             -
                               ----------------  ------------  ------------

Net Loss                       $      (432,984)  $  (597,016)  $  (608,628)
                               ================  ============  ============

Loss per common share (basic
and assuming dilution)         $         (0.02)  $     (0.04)  $     (0.04)
                               ================  ============  ============
 Weighted average common
shares outstanding                  18,939,741    14,621,627    14,304,250



</TABLE>

 The accompanying notes to unaudited condensed consolidated financial statements


<PAGE>




                           APPLIED DNA SCIENCES, INC.
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>



                                                                        For the Period
                                                    For the six months September 16, 2002
                                                          Ended      (Date of Inception)
                                                     March 31, 2003   through March 31,
                                                    ----------------        2003
                                                                        ----------
<S>                                                       <C>         <C>
Cash Flows from operating activities:
  Net loss                                                $(597,016)   $(608,628)
  Adjustments to reconcile net loss to net cash provided
by operating activities:
   Common stock issued in exchange for services             445,466     446,466
   (Decrease) Increase:
      Prepaid Expenses and Deposits                          (2,980)     (2,980)
      Other  Assets                                          (5,200)     (5,200)
  Increase (Decrease):
     Accounts payable and accrued liabilities               106,103     106,103
                                                          ----------  ----------
    Net cash provided by operating activities              (53,627))    (64,238)
Cash Flows from investing activities:                             -           -
Cash Flows from financing activities:
   Proceeds from Conversion of Common Stock                  18,000      18,000
  Advances from officers                                     61,480      72,092
                                                          ----------  ----------
   Net cash provided by financing activities                 79,480      90,092
Net increase (decrease) in cash                              25,853      25,853
Cash- beginning of period                                         -           -
                                                          ----------  ----------
Cash -end of period                                       $  25,853   $  25,853
                                                          ==========  ==========

Supplemental Disclosures:
  Interest paid for the period                            $       -           -
  Income taxes paid for the period                                -           -
  Common shares issued for services                         445,446     446,466
</TABLE>



 The accompanying notes to unaudited condensed consolidated financial statements

<PAGE>

                            APPLIED DNA SCIENCES, INC
                          (A DEVELOPMENT STAGE COMPANY)
     CONDENSED CONSOLIDATED STATEMENT OF DEFICIENCY IN STOCKHOLDERS' EQUITY
       FROM SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH MARCH 31, 2003
                                  (UNAUDITED)

<TABLE>
<CAPTION>


                                                                                               COMMON SHARES
                                                                                   -------------------------------------
<S>                                                                                <C>
Issuance of common stock to
Founders in exchange for services on

  September 16, 2002 at $0.01 per share                                                                         100,000

  Net Loss                                                                                                            -
                                                                                   -------------------------------------
  BALANCE AT SEPTEMBER 30, 2002                                                                                 100,000
  Issuance of common stock in connection with merger
  with Prohealth Medical Technologies , Inc on October 1,
  2002                                                                                                       10,178,352
  Cancellation of Common stock in connection with merger with Prohealth Medical
   Technologies , Inc on October 21, 2002                                                                      (100,000)
  Issuance of common stock in exchange for services in
   October 2002 at $0.65 per share                                                                              602,000
  Issuance of common stock in exchange for subscription in
   November and December 2002 at $0.065 per share                                                               876,000
  Net Loss                                                                                                            -
                                                                                   -------------------------------------
  BALANCE AT DECEMBER 31, 2002                                                                               11,656,352
  Cancellation of  common stock in January 2003
   previously issued  in exchange for consulting services                                                      (836,000)
  Issuance of common stock in exchange for licensing
   services valued at        $0.065 per share in January 2003                                                 1,500,000
  Issuance of common stock in exchange for consulting
   services valued at      $0.065 per share in January 2003                                                     586,250
  Issuance of common stock in exchange for consulting
   services at $0.065 per share in February  2003                                                                 9,000
  Issuance of common stock to founders 1in exchange for
   services valued at $0.0001  per share in  March 2003                                                      10,140,000
  Issuance of  common stock in exchange for consulting
   services valued at  $2.50 per share in March 2003                                                             91,060
  Issuance of common stock in exchange for consulting
   services valued at  $0.065 per share in March 2003                                                             6,000


  Net Loss                                                                                                            -
                                                                                   -------------------------------------

  BALANCE AT MARCH 31, 2003                                                                                  23,152,662
                                                                                   =====================================
                                                                                                          DEFICIT
                                                                                                         ACCUMULATED
                                                                              ADDITIONAL PAID  STOCK       DURING
                                                               COMMON STOCK     IN CAPITAL SUBSCRIPTION  DEVELOPMENT
                                                                     AMOUNT      AMOUNT     RECEIVABLE     STAGE       TOTAL
                                                                  ------------  ---------  ------------  ----------  ----------
<S>                                                               <C>           <C>        <C>           <C>         <C>



  September 16, 2002 at $0.01 per share                           $        10   $    990   $         -   $       -   $   1,000

  Net Loss                                                                  -          -             -     (11,612)    (11,612)
                                                                  ------------  ---------  ------------  ----------  ----------
  BALANCE AT SEPTEMBER 30, 2002                                            10        990             -     (11,612)    (10,612)
  Issuance of common stock in connection with
  merger with Prohealth Medical
  Technologies , Inc on October 1,
                                                                        1,000           -            -           -       1,000
  Cancellation of Common stock in connection
   with merger with Prohealth Medical
   Technologies , Inc on October 21,
                                                                            -     (1,000)            -           -      (1,000)
  Issuance of common stock in exchange for services in
   October 2002 at $0.65 per share                                         60     39,070             -           -      39,130
  Issuance of common stock in exchange for subscription in
   November and December 2002 at $0.065 per share                          88     56,852       (56,940)          -           0
  Net Loss                                                                  -          -             -    (147,191)   (147,191)
                                                                  ------------  ---------  ------------  ----------  ----------
  BALANCE AT DECEMBER 31, 2002                                          1,158     95,912       (56,940)   (158,803)   (118,673)
  Cancellation of  common stock in January 2003
   previously issued  in exchange for consulting services                 (76)   (54,264)       54,340           -           -
  Issuance of common stock in exchange for licensing
   services valued at        $0.065 per share in January 2003             150     97,350             -                   97,500
  Issuance of common stock in exchange for consulting
   services valued at $0.065 per share in January 2003                     58     76,155             -                   76,213
  Issuance of common stock in exchange for consulting
   services at $0.065 per share in February  2003                           1        584             -                      585
  Issuance of common stock to founders 1in exchange for
   services valued at $0.0001  per share in  March 2003                 1,014          -             -                    1,014
  Issuance of  common stock in exchange for consulting
   services valued at  $2.50 per share in March 2003                        9    230,625            ()           -      230,634
  Issuance of common stock in exchange for consulting
   services valued at  $0.065 per share in March 2003                       1        389             -                      390
  Issuance of common stock in exchange for cash at $0.21
   per share in March 2003                                                       18,000              -                   18,000

  Net Loss                                                                  -          -             -    (449,825)   (449,825)
                                                                  ------------  ---------  ------------  ----------  ----------

  BALANCE AT MARCH 31, 2003                                       $     2,315   $464,751   $    (2,600))  $(608,628)  $(144,162)
                                                                  ============  =========  ============  ==========  ==========
  The accompanying notes to unaudited condensed consolidated financial statements
</TABLE>

<PAGE>




                           APPLIED DNA SCIENCES , Inc.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2003

NOTE  - SUMMARY OF ACCOUNTING POLICIES

General


The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information and with the
instructions to Form 10-QSB. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been included.
Accordingly, the results from operations for the six-month period ended March
31, 2003 , are not necessarily indicative of the results that may be expected
for the year ended September 30, 2003. The unaudited condensed consolidated
financial statements should be read in conjunction with consolidated September
30, 2002 financial statements and footnotes thereto included in the as filed on
SEC Form 8-K dated October 21, 2002, as amended.

Business and Basis of Presentation

On  September  16,  2002,  Applied  DNA  Sciences,  Inc.  (the  "Company")  was
incorporated  under  the  laws  of  the State of Nevada.  The Company is  in the
development stage, as defined by Statement of Financial Accounting Standards No.
7 ("SFAS No. 7") and its efforts have been principally devoted to developing DNA
embedded  biotechnology  security  solutions in the United States.  To date, the
Company  has  generated  no  sales  revenues,  has  incurred  expenses  and  has
sustained  losses.  Consequently,  its  operations  are subject to all the risks
inherent  in  the  establishment  of a new business enterprise.   For the period
from  inception  through  March 31, 2003, the Company  has accumulated losses of
$608,628.

The consolidated financial statements include the accounts of the Company, and
its wholly owned subsidiary ProHealth Medical Technologies, Inc. Significant
company transactions have been eliminated in Consolidation.

Reclassification

Certain prior period amounts have been reclassified for comparative purposes.


NOTE B- ACQUISITION

On October 21, 2002, the Company entered into a Plan and Agreement of
Reorganization ("Merger") with ProHealth Medical Technologies, Inc.
("ProHealth") an inactive publicly registered shell corporation with no
significant assets or operations. For accounting purposes, the Company shall be
the surviving entity. The transaction is accounted for using the purchase method
of accounting. The total purchase price and carrying value of net assets
acquired of was $ 880. From November 1988 until the date of the merger,
ProHealth was an inactive corporation with no significant assets and liabilities

Effective with the Merger , all previously outstanding common stock, preferred
stock, options and warrants owned by the Company's shareholders were exchanged

<PAGE>

for an aggregate of 11,000,000 shares of ProHealth common stock. The value of
the stock that was issued was the historical cost of the ProHealth's net
tangible assets, which did not differ materially from their fair value. In
accordance with Accounting Principles Board Opinion No. 16, the Company is the
acquiring entity.

Effective with the Merger, ProHealth changed its name to Applied DNA Sciences,
Inc.


ITEM 2.  MANAGEMENTS  DISCUSSION  AND ANALYSIS OR PLAN OF OPERATIONS FOR THE SIX
         MONTHS ENDED MARCH 31, 2003

The following discussion should be read in conjunction with the Company's
Consolidated Financial Statements and Notes thereto, included elsewhere within
this report. The quarterly report contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended, including statements using
terminology such as "can", "may", "believe", "designated to", "will", "expect",
"plan", "anticipate", "estimate", "potential" or "continue", or the negative
thereof or other comparable terminology regarding beliefs, plans, expectations
or intentions regarding the future. Forward looking statements involve risks and
uncertainties and actual results could differ materially from those discussed in
forward-looking statements. All forward looking statements and risk factors
included in this document are made as of the date hereof, based on information
available to the Company as of the date thereof, and the Company assumes no
obligations to update any forward-looking statement or risk factor, unless the
Company is required to do so by law.

Plan of Operation
-----------------

The  Company  presently  does  not  have any available credit, bank financing or
other  external  sources  of  liquidity. Due to historical operating losses, the
Company's  operations have not been a source of liquidity. The Company will need
to  obtain  additional  capital  in  order  to  expand  operations  and  become
profitable.  The  Company intends to pursue the granting of sub-licenses outside
the  United  States,  and  if  successful,  the  granting  of sub-licenses would
constitute a substantial additional source of liquidity and capital. In order to
obtain  capital,  the  Company  may need to sell additional shares of its common
stock  or  borrow funds from private lenders. There can be no assurance that the
Company  will  be  successful  in  obtaining  additional funding and granting of
sub-licenses  outside  the  Unites  States.

During  the  six  months  ended March 31, 2003, the Company's priorities were to
recruit  and  build  its  team, organize its new infrastructure and to develop a
successful strategy how best to exploit its Biowell license agreement, therefore
no  revenues  were  anticipated, planned or received, expenses of  $597,016 were
incurred  stemming  from general, selling, and administrative expenses; $445,466
of  these expenses were paid with 2,192,310 shares of the Company's common stock
to  consultants for management services rendered. Although the management of the
Company  is  of the opinion that continuing to develop and finance the Company's
present  business of providing DNA anti-counterfeit technology may ultimately be
successful,  management  nevertheless  expects  that  the  Company  will  need
substantial  additional  capital  before  the  Company's operations can be fully
implemented.

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

As  of  March  31,  2003,  we  had a working capital deficit of $ 144,162 . As a
result  of  our  operating  losses from our inception through March 31, 2003, we
generated a cash flow deficit of ($53,627) from operating activities. We met our
cash requirements during this period from advances of $61,480 from the Company's
officer  and  principal shareholders, and from the exercise of previously issued
options  which  contributed  proceeds  of  $18,000.

While  we have raised capital to meet our working capital and financing needs in
the  past,  additional  financing  is  required in order to meet our current and
projected  cash  flow  deficits  from operations and development. We are seeking
financing  in  the  form  of  equity  in  order to provide the necessary working
capital.  We  currently have no commitments for financing. There is no guarantee
that  we  will  be  successful  in  raising  the  funds  required.

By adjusting its operations and development  to the level of capitalization ,
management believes it has sufficient capital  resources to meet  projected cash
flow deficits through the next twelve months . However, if thereafter, we are
not successful in generating sufficient liquidity from operations or in raising
sufficient capital resources, on terms acceptable to us, this could have a
material adverse effect on our business, results of operations , liquidity and
financial condition.


<PAGE>
The effect of inflation on the Company's revenue and operating results was not
significant. The Company's operations are located  in North America  and there
are no seasonal aspects that would have a material effect on the Company's
financial condition or results of operations.


The  Company's  independent certified public accountant has stated in his report
included  in  the  Company's  October  21,  2002  Form 8-K, as amended, that the
Company  has incurred operating losses from its inception , and that the Company
is  dependent  upon management's ability to develop profitable operations. These
factors  among others may raise substantial doubt about the Company's ability to
continue  as  a  going  concern.

PRODUCT RESEARCH AND DEVELOPMENT
--------------------------------

We do not anticipate incurring material  research and development costs during
the next twelve months.


ACQUISITION OF PLANT AND EQUIPMENT AND OTHER ASSETS
---------------------------------------------------

We  do  not  anticipate  the  sale of any material property , plant or equipment
during  the next 12 months. We do not anticipate the acquisition of any material
property,  plant  or  equipment  during  the  next  12  months.

NUMBER OF EMPLOYEES
-------------------

From  our  inception through the period ended March 31, 2003 , we have relied on
the  services  of  outside  consultants  for services and have no employees.  In
order for us to attract and retain quality personnel, we anticipate we will have
to  offer  competitive  salaries to future employees.  We anticipate that it may
become  desirable to add additional full and or part time employees to discharge
certain  critical functions during the next 12 months.   This projected increase
in  personnel  is  dependent  upon  our  ability to generate revenues and obtain
sources  of  financing.  There  is  no  guarantee  that we will be successful in
raising  the  funds  required  or  generating  revenues  sufficient  to fund the
projected increase in the number of employees. As we continue to expand, we will
incur  additional  cost  for  personnel.

TRENDS, RISKS AND UNCERTAINTIES
-------------------------------

We  have  sought to identify what we believe to be the most significant risks to
our  business,  but  we  cannot  predict whether, or to what extent, any of such
risks  may be realized nor can we guarantee that we have identified all possible
risks  that  might  arise.  Investors should carefully consider all of such risk
factors  before  making an investment decision with respect to our Common Stock.

RISKS

Applied  DNA  Sciences,  Inc.,  is  a  small  company  entering  a technical and
specialized  scientific  industry.  The  Company's  growth  will depend upon the
working  capital  and financial support, which we are in the process of seeking.
The  Company  will  need  substantial  additional capital to expand and compete.
While  the  management  team  has  strong contacts in the geographic and product
territories,  the  Company  is small with limited assets and a limited operating
history  and  may,  as  a  result,  have  difficulties securing large enough and
increasing  financial commitments from potential investors. Thus the Company may
be  subject  to  the  high  risks  associated  with start-up companies and small
business.

The  Company  relies on a small number of key individuals to implement plans and
operations.  Although  the Company may obtain key person life insurance coverage
on  the  Company's  key  individuals,  the Company has not done so at this time.
Should  for  some  reason their services become unavailable, the Company will be
required  to  retain  other  qualified  personnel.

Reductions  or  delays  in  research  and  development budgets and in government
funding  may  negatively  impact the Company's sales. Future clients may include
researchers at pharmaceutical and biotechnology companies, academic institutions
and  government  and  private  laboratories.  Fluctuations  in  the research and
development  budgets  of  these researchers and their organizations could have a
significant  effect  on  demand  for  the  Company's  products.  Research  and
development  budgets  fluctuate  due  to  numerous  factors that are outside the
Company's  control and are difficult to predict, including changes  in available
<PAGE>
resources,  spending  priorities  and  institutional  budgetary  policies.  The
Company's  business  could  be seriously damaged by any decrease in life science
research  and  development  expenditures  by pharmaceutical and biotechnological
companies,  academic  institutions  or  government  and  private  laboratories.
Although  the  level  of  research funding has increased during the past several
years,  we  cannot  assure  that this trend will continue. Government funding of
research  and  development  is  subject  to  the  political  process,  which  is
inherently  fluid  and  unpredictable.  Also  government proposals to  reduce or
eliminate  budgetary deficits have sometimes included reduced allocations to the
US  National  Institute  of  Health  and  other  government  agencies  that fund
research and development activities. Also, our potential customers receive funds
from  approved  grants  at  particular  times  of the year, as determined by the
federal  government.  Grants have, in the past, been frozen for extended periods
or  have  otherwise  become  unavailable to various institutions without advance
notice.  The  timing  of  receipt  of grant funds affects the timing of purchase
decisions by our customers and, as a result, can cause fluctuations in our sales
and  operating  results.

The Company regards trademarks, trade secrets and other intellectual property as
a component of its success, The Company relies on trademark law and trade secret
protection  and  confidentiality  and  /or  license agreements with consultants,
customers,  partners  and others to protect our intellectual property. Effective
trademark  and  trade secret protection may not be available in every country in
which  the  Company's products are available. The Company cannot be certain that
the  Company  has  taken  adequate  steps  to protect its intellectual property,
especially  in  countries where the laws may not protect the Company's rights as
fully  as  in  the  United  States.  In  addition,  the  Company's  third  party
confidentiality  agreements  can  be breached and, if they are, there may not be
adequate  remedy available to the Company. If the Company's trade secrets become
known,  the  Company  may  lose  its  competitive  edge.

The  Company  may  be  unable to protect its trademarks, trade secrets and other
intellectual  property  rights  that  are important to its business. The Company
regards  its  trademarks,  trade  secrets  and  other intellectual property as a
component of its success. The Company  relies  on trademark law and trade secret
protection  and  confidentiality  and/or  license  agreements  with consultants,
employees,  customers, partners and others to protect our intellectual property.

Litigation as regards the Company intellectual property or other subject matters
could  harm  the  Company's  business.  Litigation  regarding  patents and other
intellectual  property  rights  is  extensive in the biotechnology industry. The
Company is aware that patents have been applied for, and in some cases issued to
others,  claiming technologies that are closely related to Applied DNA Sciences,
Inc.  As  a  result, and in part due  to the ambiguities  and evolving nature of
intellectual  property  law,  the  Company  periodically  receives  notices  of
potential  infringements of patents held by others. Although to date the Company
has  successfully resolved these types of claims, the Company may not be able to
do  so  in  the  future.  In  the event of an intellectual property dispute, the
Company  may  be  forced  to litigate. This litigation could involve proceedings
declared  by  the  U.S.  Patent  and Trademark Office or the International Trade
Commission,  as well as proceedings brought directly by affected third parties.
Intellectual  property  litigation  can  be  extremely  expensive,  and  these
expenses,  as  well  as  the  consequences should the Company not prevail, could
seriously  harm the Company's business, If a third party claimed an intellectual
property  right  to  technology  the  Company  uses,  the  Company might need to
discontinue  an  important  product  or  product  line,  alter  its products and
processes,  pay license fees or cease its affected business activities, Although
the  Company might under these circumstances attempt to obtain a license to this
intellectual  property,  it  may  not be able to do so on favorable terms, or at
all.

In  addition  to intellectual property litigation, other substantial, complex or
extended  litigation  could  result  in  large expenditures for the Company  and
distraction  of  its  management.  For  example,  law  suits  by  employees,
shareholders,  collaborators  or  distributors  could  be  very  costly  and
substantially  disrupt  the  Company's business. Disputes from time to time with
companies or individuals are not uncommon in the industry and the Company cannot
assure  that  it  will  always  be  able  to  resolve  them  out  of  court.

The  Company's  growth  depends  upon  the ability to undertake sales in current
markets  and  to  expand  sales  nationally to additional market segments and to
Europe.  There  can be  no certainty that the Company's efforts to increase  and
expand  sales  can be accomplished on a profitable basis. The expansion to other
delivery  methods  and  to other venues will depend on a number of factors, most
notably  the timely and successful  promotion and sale of the Company's products
and  related  services.  The  Company's  inability  to expand sales, in a timely
manner,  would have a material adverse effect on its business, operating results
and  its  financial  condition.
<PAGE>

ITEM  3.  CONTROLS  AND  PROCEDURES
-----------------------------------

The  Company's  management  including the Chief Executive Officer, President and
Chief  Financial  Officer, have evaluated, within 90 days prior to the filing of
this  quarterly  report,  the  effectiveness  of  the  design,  maintenance  and
operation  of  the  Company's  disclosure  controls  and  procedures. Management
determined  that the Company's disclosure controls and procedures were effective
in  ensuring that the information required to be disclosed by the Company in the
reports  that  it  files  under  the  Exchange  Act is accurate and is recorded,
processed  ,  summarized  and  reported within the time periods specified in the
Commission's  rules  and  regulations.

Disclosure controls and procedures, no matter how well designed and implemented,
can  provide  only  reasonable  assurance  of  achieving  an entity's disclosure
objectives.  The  likelihood  of  achieving  such  objectives  is  affected  by
limitations  inherent  in  disclosure controls and procedures. These include the
fact  that  human  judgment  in  decision  making  can  be fully faulty and that
breakdowns  in  internal  control  can  occur  because of human failures such as
errors  or  mistakes  or  intentional  circumvention of the established process.

There  have been no significant changes in internal controls or in other factors
that  could  significantly  affect  these controls subsequent to the date of the
evaluation  thereof, including any corrective actions with regard to significant
deficiencies  and  material  weaknesses.



<PAGE>


PART II:          OTHER INFORMATION

ITEM 1.           LEGAL PROCEEDINGS



ITEM 2.           CHANGES IN SECURITIES

                  NONE


ITEM 3.           DEFAULTS UPON SENIOR SECURITIES

                  NONE

ITEM 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

                  NONE

ITEM 5.           OTHER INFORMATION

                   The Company holds an option to buy back 8,500,000 shares
                   from Glen Little for $100,000. Glen Little was the President
                   of ProHealth Medical Technologies, Inc.

                   Mr. Little has agreed to return the 8,500,000 shares to the
                   Company for cancellation in exchange for an interest bearing
                   $100,000 Convertible Capital Note. This transaction should
                   be completed before June 30, 2003.





ITEM 6.           EXHIBITS AND REPORTS ON FORM 8-K

(a)      Exhibits

99.1 Certification  pursuant to 18 U.S.C.  Section  1350 as adopted  pursuant to
     Section 906 of the  Sarbanes-Oxley  Act of 2002 -- Chief Executive  Officer
     (filed herewith).


99.2 Certification  pursuant to 18 U.S.C.  Section  1350 as adopted  pursuant to
     Section 906 of the  Sarbanes-Oxley  Act of 2002 --Chief  Financial  Officer
     (filed herewith).

(b) Reports on Form 8-K filed during the three months ended March 31, 2003

                  On February 5, 2003, a Current Report was filed on Form 8-K
     disclosing the change in the Company's fiscal year-end to September 30. On
     April 17, 2003, another Current Report was filed on Form 8-K disclosing a
     press release regarding the fact that the Company's DNA-based Textile
     Marker System selected as one of three technologies as a key solution for
     U.S. textile manufacturers and the customs service to combat illegal
     textile imports.



                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date:  May 15, 2003.                     Applied DNA Sciences, Inc.

                                         /s/ Lawrence Lee
                                         ----------------------
                                         Lawrence Lee
                                         Chief Executive Officer

                                         /s/Gerhard Wehr
                                         ----------------------
                                         Gerhard Wehr
                                         Chief Financial Officer


<PAGE>

                                  CERTIFICATION
                                  --------------

I, Lawrence Lee, Chief Executive Officer, and, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Applied DNA Sciences,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have: a) designed
such disclosure controls and procedures to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in
which this quarterly report is being prepared; b) evaluated the effectiveness of
the registrant's disclosure controls and procedures as of a date within 90 days
prior to the filing date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions): a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: May 15, 2003

                                            /s/ Lawrence Lee
                                            ---------------------------
                                            Name: Lawrence Lee
                                            Title: Chief Executive Officer




<PAGE>


                                  CERTIFICATION

I, Gerhard Wehr, Chief  Financial  Officer, and, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Applied DNA Sciences,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have: a) designed
such disclosure controls and procedures to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in
which this quarterly report is being prepared; b) evaluated the effectiveness of
the registrant's disclosure controls and procedures as of a date within 90 days
prior to the filing date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions): a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: May 15, 2003


                                      /s/    Gerhard Wehr
                                      Name:  Gerhard Wehr
                                      Title: Chief Financial Officer







<PAGE>